Philippines - English - FDA (Food And Drug Administration)

sanofi-aventis philippines, inc. - insulin glargine , lixisenatide - solution for injection (sc) - 3.64 mg (equivalent to 100 units of insulin glargine/33 mcg per ml solution

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - insulin glargine (genetical recombination); lixisenatide - clear and colorless injection, (band/injection button) magenta

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - not applicable

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

novo nordisk a/s - liraglutide - solution for s/c injection - 6mg/ml

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - liraglutide - injection, solution - 6mg/ml - liraglutide 6mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - liraglutide - solution for injection - 6mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - gliclazide - modified-release tablet - 60 milligram(s) - sulfonamides, urea derivatives; gliclazide

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - obesity; overweight - drugs used in diabetes - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - liraglutide, quantity: 6 mg/ml - injection, solution - excipient ingredients: phenol; hydrochloric acid; water for injections; propylene glycol; dibasic sodium phosphate dihydrate; sodium hydroxide - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of:,- greater than or equal to 30 kg/m2 (obese) or,- greater than or equal to 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.,treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.